Compugen Doses First Patient in COM701 Ovarian Cancer Trial
July 21, 2025
Randomized sub-trial 1 of a global adaptive platform trial of COM701 maintenance therapy in patients with relapsed platinum sensitive ovarian cancer Compugen Ltd, a clinical-stage